Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025

Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company based in Carmiel, Israel, will announce its financial results for the third quarter of 2025 on November 13, 2025. The company focuses on the development and commercialization of recombinant therapeutic proteins using its proprietary plant cell-based expression system, ProCellEx®. Protalix stands out as the first company to receive FDA approval for a protein produced through this innovative method, highlighting its commitment to advancing biopharmaceutical manufacturing.

The upcoming financial results will cover the quarter ended September 30, 2025, and will provide insights into the company's performance as well as updates on its ongoing business activities. To discuss the financial results and recent developments, management will host a conference call at 8:00 a.m. Eastern Standard Time (EST). Investors and interested parties are encouraged to join the call, which can be accessed via toll-free or international numbers, or through a live webcast available on Protalix's official website.

Protalix's product portfolio includes taliglucerase alfa, the first product it commercialized through ProCellEx, for treating Gaucher disease, with licensing rights held by Pfizer Inc. for global development, except in Brazil. Additionally, the company launched its second product, Elfabrio®, which received approval from both the FDA and the European Medicines Agency in May 2023, in collaboration with Chiesi Farmaceutici S.p.A. Protalix is advancing an array of promising candidates in its pipeline, which includes PRX–115 for uncontrolled gout and PRX–119 for NETs-related diseases, positioned to impact significant pharmaceutical markets.

For more information on the conference call and accompanying webcast, participants are advised to register ahead of time and can access the replay on Protalix’s investor relations page for two weeks post-event.

As Protalix BioTherapeutics (NYSE American: PLX) prepares to announce its third quarter 2025 financial results on November 13, it presents a pivotal moment for investors to assess the company’s trajectory in the biopharmaceutical sector. Given the recent approval of its product Elfabrio® and its licensing agreement with Pfizer for taliglucerase alfa, Protalix is increasingly positioned as a front-runner in the production of recombinant therapeutic proteins through its innovative ProCellEx® expression system.

One should examine the company’s financials closely during the call scheduled for 8:00 a.m. EST, as the results could significantly impact PLX’s stock performance. Analysts should look for revenue growth from Elfabrio® sales, given its recent regulatory approvals. Success in this drug’s commercialization could catalyze investor confidence and potentially drive share prices upward.

Furthermore, insights into Protalix’s development pipeline, including PRX–115 and PRX–119—targeting key therapeutic markets—merit attention. Any updates regarding partnerships or trial results can reflect the robustness of their R&D strategy and market readiness.

Investors should also be aware of the market sentiment surrounding the biopharmaceutical industry as a whole, particularly in light of evolving healthcare policies and competition from other emerging therapies. Given current economic conditions, a cautious approach is advisable while being poised to capitalize on positive developments.

In conclusion, considering Protalix’s unique position within its niche, the outcomes from the upcoming earnings call and any new strategic partnerships could serve as substantial indicators of future performance. Additionally, these insights will provide valuable information for making informed investment decisions in the coming months.